Demographic characteristics of AML patients grouped by osteocalcin level in peripheral blood
| Characteristic . | Osteocalcin ≤11 ng/mL . | Osteocalcin >11 ng/mL . |
|---|---|---|
| No. of patients | 24 | 34 |
| Median age (range), y | 63 (25-79) | 61.5 (35-88) |
| Age >60 y, n (%) | 13 (54.2) | 18 (52.9) |
| Male, n (%) | 7 (29.2) | 18 (52.9) |
| European LeukemiaNet, n | 1 patient missing | 2 patients missing |
| Favorable | 3 | 3 |
| Intermediate I | 12 | 17 |
| Intermediate II | 2 | 4 |
| Unfavorable | 6 | 8 |
| Median blood counts (IQR) | ||
| WBC, ×109/L | 46.49 (6.53-122.79) | 2.75 (1.53-12.51) |
| Absolute neutrophil count, ×109/L | 0 (0-0.08) | 0.255 (0-0.525) |
| Peripheral blood blasts, % | 82.5 (29-88) | 10.5 (2.75-27) |
| Hemoglobin, g/dL | 9.1 (8.1-10.1) | 9.2 (8.25-10.93) |
| Platelet count, ×109/L | 55 (24.75-89) | 78 (40-130.75) |
| Median bone marrow (IQR) | ||
| Blast count by cytology, % | 85 (62.5-90); 8 patients missing | 55 (31.25-85); 8 patients missing |
| Treatment modality, n (%) | ||
| Curative | 17 (70.8) | 24 (70.6) |
| Palliative | 7 (29.2) | 10 (29.4) |
| Median days of follow-up (range) | 247 (10-982) | 355 (175-601) |
| Characteristic . | Osteocalcin ≤11 ng/mL . | Osteocalcin >11 ng/mL . |
|---|---|---|
| No. of patients | 24 | 34 |
| Median age (range), y | 63 (25-79) | 61.5 (35-88) |
| Age >60 y, n (%) | 13 (54.2) | 18 (52.9) |
| Male, n (%) | 7 (29.2) | 18 (52.9) |
| European LeukemiaNet, n | 1 patient missing | 2 patients missing |
| Favorable | 3 | 3 |
| Intermediate I | 12 | 17 |
| Intermediate II | 2 | 4 |
| Unfavorable | 6 | 8 |
| Median blood counts (IQR) | ||
| WBC, ×109/L | 46.49 (6.53-122.79) | 2.75 (1.53-12.51) |
| Absolute neutrophil count, ×109/L | 0 (0-0.08) | 0.255 (0-0.525) |
| Peripheral blood blasts, % | 82.5 (29-88) | 10.5 (2.75-27) |
| Hemoglobin, g/dL | 9.1 (8.1-10.1) | 9.2 (8.25-10.93) |
| Platelet count, ×109/L | 55 (24.75-89) | 78 (40-130.75) |
| Median bone marrow (IQR) | ||
| Blast count by cytology, % | 85 (62.5-90); 8 patients missing | 55 (31.25-85); 8 patients missing |
| Treatment modality, n (%) | ||
| Curative | 17 (70.8) | 24 (70.6) |
| Palliative | 7 (29.2) | 10 (29.4) |
| Median days of follow-up (range) | 247 (10-982) | 355 (175-601) |